CLINICAL TRIALS PROFILE FOR TRILOSTANE

All Clinical Trials for TRILOSTANE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00181597 ↗	Trilostane for Androgen-Independent Prostate Cancer	Completed	Genzyme, a Sanofi Company	Phase 2	2004-03-01	The main purpose of this study is to test the safety of trilostane by looking at what effects, good and bad, it has on patients with androgen-independent prostate cancer.
NCT01615211 ↗	Randomized Study of Letrozole and Trilostane for Medical Abortion	Terminated	Karolinska Institutet	Phase 2	2012-05-01	In menstruation an effective shedding of the endometrial lining occurs. Both progesterone and estrogen levels fall sharply at this time. During medical abortion the endometrial shedding is sometimes ineffective causing an incomplete abortion which may cause prolonged bleeding or require surgical intervention. In medical abortion a progesterone antagonist is used as treatment but the estrogen levels are not targeted. The investigators wish to explore whether addition of letrozole or trilostane which target estrogen levels can lead to a more effective shedding of the endometrial lining.
NCT01615211 ↗	Randomized Study of Letrozole and Trilostane for Medical Abortion	Terminated	The University of Hong Kong	Phase 2	2012-05-01	In menstruation an effective shedding of the endometrial lining occurs. Both progesterone and estrogen levels fall sharply at this time. During medical abortion the endometrial shedding is sometimes ineffective causing an incomplete abortion which may cause prolonged bleeding or require surgical intervention. In medical abortion a progesterone antagonist is used as treatment but the estrogen levels are not targeted. The investigators wish to explore whether addition of letrozole or trilostane which target estrogen levels can lead to a more effective shedding of the endometrial lining.
NCT01615211 ↗	Randomized Study of Letrozole and Trilostane for Medical Abortion	Terminated	Kristina Gemzell Danielsson	Phase 2	2012-05-01	In menstruation an effective shedding of the endometrial lining occurs. Both progesterone and estrogen levels fall sharply at this time. During medical abortion the endometrial shedding is sometimes ineffective causing an incomplete abortion which may cause prolonged bleeding or require surgical intervention. In medical abortion a progesterone antagonist is used as treatment but the estrogen levels are not targeted. The investigators wish to explore whether addition of letrozole or trilostane which target estrogen levels can lead to a more effective shedding of the endometrial lining.

Clinical Trial Conditions for TRILOSTANE

Condition Name

Condition Name for TRILOSTANE
Intervention	Trials
Medical Abortion, Complete or Unspecified, Without Complication	1
Prostate Adenocarcinoma	1
Prostate Cancer	1

Condition MeSH

Condition MeSH for TRILOSTANE
Intervention	Trials
Adenocarcinoma	1
Prostatic Neoplasms	1

Clinical Trial Locations for TRILOSTANE

Trials by Country

Trials by Country for TRILOSTANE
Location	Trials
United States	1
Sweden	1

Trials by US State

Trials by US State for TRILOSTANE
Location	Trials
Massachusetts	1

Clinical Trial Progress for TRILOSTANE

Clinical Trial Phase

Clinical Trial Phase for TRILOSTANE
Clinical Trial Phase	Trials
Phase 2	2

Clinical Trial Status

Clinical Trial Status for TRILOSTANE
Clinical Trial Phase	Trials
Completed	1
Terminated	1

Clinical Trial Sponsors for TRILOSTANE

Sponsor Name

Sponsor Name for TRILOSTANE
Sponsor	Trials
Genzyme, a Sanofi Company	1
Karolinska Institutet	1
The University of Hong Kong	1

Sponsor Type

Sponsor Type for TRILOSTANE
Sponsor	Trials
Other	3
Industry	1